Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

Double-blind, placebo-controlled, randomized clinical trial comparing HGH to placebo in maximal stimulation in an IVF cycle.

HGH or placebo were added from the start of the cycle in a double-blinded manner.

The primary outcome was live birth rate.

What Was Measured

PubMed files the paper under topics including Birth Rate, Body Mass Index, Fertilization in Vitro, Follicle Stimulating Hormone, Human Growth Hormone, Infertility, Female and Infertility, Male.

The authors tagged it with the keywords IVF, Live birth, Poor responders and Randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Reproductive biomedicine online), a journal based in Netherlands.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.